Terug
Dagbereik
€ 22,30
€ 26,00
52-Weeksbereik
€ 22,30
€ 28,12
Volume
2
50D / 200D Gem.
€ 26,04
/
€ 26,36
Vorige Slotkoers
€ 26,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,1 | 0,3 |
| P/B | 0,0 | 2,9 |
| ROE % | 9,4 | 3,7 |
| Net Margin % | 14,8 | 3,8 |
| Rev Growth 5Y % | 5,8 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 79,80
€ 72,49 – € 85,09
|
71 B | 1 |
| FY2029 |
€ 66,80
€ 60,68 – € 71,23
|
73 B | 1 |
| FY2028 |
€ 39,17
€ 35,58 – € 41,77
|
80 B | 1 |
Belangrijkste Punten
Revenue grew 5,82% annually over 5 years — modest growth
Earnings grew 73,77% over the past year
Debt/Equity of 0,03 — conservative balance sheet
Generating 25,39B in free cash flow
P/E of 0,07 — trading at a low valuation
PEG of 0,15 suggests growth is underpriced
Groei
Revenue Growth (5Y)
5,82%
Revenue (1Y)30,52%
Earnings (1Y)73,77%
FCF Growth (3Y)89,81%
Kwaliteit
Return on Equity
9,41%
ROIC10,08%
Net Margin14,83%
Op. Margin22,37%
Veiligheid
Debt / Equity
0,03
Current Ratio3,67
Interest Coverage751,21
Waardering
P/E Ratio
0,07
P/B Ratio0,01
EV/EBITDA-2,34
Dividend Yield0,05%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 30,52% | Revenue Growth (3Y) | 13,51% |
| Earnings Growth (1Y) | 73,77% | Earnings Growth (3Y) | 60,11% |
| Revenue Growth (5Y) | 5,82% | Earnings Growth (5Y) | 0,99% |
| Profitability | |||
| Revenue (TTM) | 94,04B | Net Income (TTM) | 13,95B |
| ROE | 9,41% | ROA | 7,32% |
| Gross Margin | 62,24% | Operating Margin | 22,37% |
| Net Margin | 14,83% | Free Cash Flow (TTM) | 25,39B |
| ROIC | 10,08% | FCF Growth (3Y) | 89,81% |
| Safety | |||
| Debt / Equity | 0,03 | Current Ratio | 3,67 |
| Interest Coverage | 751,21 | Dividend Yield | 0,05% |
| Valuation | |||
| P/E Ratio | 0,07 | P/B Ratio | 0,01 |
| P/S Ratio | 0,01 | PEG Ratio | 0,15 |
| EV/EBITDA | -2,34 | Dividend Yield | 0,05% |
| Market Cap | 984,58M | Enterprise Value | -49,26B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 94,04B | 72,04B | 72,98B | 76,03B | 74,98B |
| Net Income | 13,95B | 8,03B | 5,44B | 9,55B | 13,41B |
| EPS (Diluted) | 365,42 | 212,66 | 144,79 | 251,44 | 347,37 |
| Gross Profit | 58,53B | 38,54B | 39,56B | 41,58B | 40,91B |
| Operating Income | 21,03B | 9,51B | 8,00B | 17,06B | 17,79B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 190,42B | 171,62B | 166,33B | 165,18B | 163,33B |
| Total Liabilities | 37,79B | 27,87B | 29,49B | 26,86B | 27,08B |
| Shareholders' Equity | 152,63B | 143,76B | 136,26B | 137,75B | 136,26B |
| Total Debt | 3,85B | 3,85B | 3,85B | 3,85B | 3,85B |
| Cash & Equivalents | 54,09B | 50,63B | 59,56B | 61,03B | 63,71B |
| Current Assets | 111,38B | 106,97B | 109,90B | 110,61B | 113,66B |
| Current Liabilities | 30,35B | 19,02B | 20,84B | 19,05B | 21,28B |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026